Literature DB >> 12799369

Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin.

Sushil K Mahata1, Nitish R Mahapatra, Manjula Mahata, Timothy C Wang, Brian P Kennedy, Michael G Ziegler, Daniel T O'Connor.   

Abstract

Stimulation of chromaffin cell secretion in vitro triggers not only secretion but also resynthesis of just released catecholamines and chromogranin A, the precursor of the catecholamine release-inhibitory, nicotinic cholinergic antagonist peptide catestatin. Does stimulus-transcription coupling occur in vivo? And does catestatin antagonize secretion and transcription in vivo? To answer these questions, we employed a novel mouse strain harboring a chromogranin A promoter/firefly luciferase reporter transgene. Tissue-specific expression of the reporter was established by both luminescence and reverse transcription-PCR. Secretion and transcription in vivo were triggered by either direct nicotinic stimulation or vesicular transmitter depletion. Nicotinic blockade in vivo was attempted with either the classical antagonist chlorisondamine or the novel antagonist catestatin. Luciferase reporter expression was exquisitely sensitive over a large dynamic range, was specific for the transgenic animals, and paralleled typical neuroendocrine distribution of endogenous chromogranin A. Adrenal ontogeny revealed a rise of embryonic transgene expression until embryonal day 18, with an abrupt postnatal decline. Direct nicotinic stimulation of chromaffin cells caused catecholamine release and transgene transcription, each of which was nearly completely blocked by chlorisondamine. Similar adrenal results were obtained during vesicular catecholamine depletion. Both secretion and transcription were substantially blocked in the adrenal gland by catestatin. In brain and sympathetic nerve, stimulation of transcription was more modest, and reserpine responses were only incompletely blocked by chlorisondamine or catestatin, perhaps because of limited blood-brain barrier penetration by these cationic antagonists. Thus, nicotinic cholinergic stimulus-transcription coupling occurs in vivo and can be provoked either directly or indirectly (by vesicular transmitter depletion). Such coupling triggers the biosynthesis of chromogranin A, the precursor of catestatin. Catestatin itself blocks stimulation of both secretion and transcription in vivo. Thus, chromogranin A and its catestatin fragment may lie at the nexus of nicotinic cholinergic signaling in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799369     DOI: 10.1074/jbc.M305545200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.

Authors:  Nitish R Mahapatra; Daniel T O'Connor; Sucheta M Vaingankar; Amiya P Sinha Hikim; Manjula Mahata; Saugata Ray; Eugenie Staite; Hongjiang Wu; Yusu Gu; Nancy Dalton; Brian P Kennedy; Michael G Ziegler; John Ross; Sushil K Mahata
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

3.  Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout mice.

Authors:  Kechun Tang; Teresa Pasqua; Angshuman Biswas; Sumana Mahata; Jennifer Tang; Alisa Tang; Gautam K Bandyopadhyay; Amiya P Sinha-Hikim; Nai-Wen Chi; Nicholas J G Webster; Angelo Corti; Sushil K Mahata
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

4.  Application of the Co-culture Membrane System Pointed to a Protective Role of Catestatin on Hippocampal Plus Hypothalamic Neurons Exposed to Oxygen and Glucose Deprivation.

Authors:  Maria Mele; Sabrina Morelli; Gilda Fazzari; Ennio Avolio; Raffaella Alò; Antonella Piscioneri; Loredana De Bartolo; Rosa Maria Facciolo; Marcello Canonaco
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

5.  Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout.

Authors:  Sucheta M Vaingankar; Ying Li; Angelo Corti; Nilima Biswas; Jiaur Gayen; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-15       Impact factor: 3.107

6.  Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo.

Authors:  Teresa Pasqua; Sumana Mahata; Gautam K Bandyopadhyay; Angshuman Biswas; Guy A Perkins; Amiya P Sinha-Hikim; David S Goldstein; Lee E Eiden; Sushil K Mahata
Journal:  Cell Tissue Res       Date:  2015-11-16       Impact factor: 5.249

Review 7.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

8.  Stress-induced changes in adrenal neuropeptide Y expression are regulated by a negative feedback loop.

Authors:  Qian Wang; Matthew D Whim
Journal:  J Neurochem       Date:  2013-02-17       Impact factor: 5.372

9.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

10.  Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse.

Authors:  Jiaur R Gayen; Yusu Gu; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.